Breaking News
War Comes Closer: Senate OK's $40 Billion To Ukraine; NATO Pledges 'Open Ended' Support
Get Ready to Be Muzzled: The Coming War on So-Called Hate Speech
California Judge Strikes Down Law Forcing Companies To Appoint Women To Corporate Boards
Elon Musk's Twitter Detractors Were Subsidized With Millions In Taxpayer Dollars
Top Tech News
World's First Vertiport For Flying Taxis Opens In UK
The World's First Flying Taxi Hub Takes Shape in the English Midlands
Elon Musk Gives Everyday Astronaut a SpaceX Starbase Tour
NEW StarLink Mesh Nodes | Starlink | Starlink 2022
Episode 5: What to do in a BOIL ADVISORY with your Berkey Filter
Harley-Davidson's Livewire announces second electric motorcycle
ColdQuanta Cold Atom Quantum Computer is Commercially Available
Styro Aircrete Garden Shed- Pouring and Packing the Walls
Watch: Autonomous Chinese Drone Swarm Flies Through Forest While Hunting For Humans
We test drove a solar powered car with 1000 miles range that never needs charging
DARPA Nucleic Technology Funded to Get Virus Response to 1-60 Days
The P3 teams are developing technologies to deliver antibodies using nucleic acid technology, and achieve sufficient serum concentrations of the antibodies for protection against the pathogen within three days after administration.
DARPA has programs for Pandemic Prevention Platform, Nucleic Acids On-Demand Worldwide (NOW), and PReemptive Expression of Protective Alleles and Response Elements (PREPARE) programs.
Nucleic Acids On-Demand Worldwide (NOW)
The goal of the NOW program is to develop a mobile medical countermeasure (MCM) manufacturing platform for use in stabilization and humanitarian operations to produce, formulate, and package hundreds of doses of nucleic acid therapeutics (DNA and/or RNA) in less than 24 hours. The developed platform should be a resilient, mobile, readily accessible nucleic acid MCM manufacturing capability that enables immediate threat response anywhere the military operates with minimal user intervention.